The Efficacy of Allo-HSCT in ND HR-CBF-AML

This study is testing whether a bone marrow transplant from a matched donor (allogeneic hematopoietic stem cell transplantation, or allo-HSCT) can improve outcomes for people newly diagnosed with a specific type of acute myeloid leukemia (AML) called core binding factor AML (CBF-AML) that carries high-risk features. **You may be eligible if...** - You have been diagnosed with CBF-AML, confirmed by genetic testing showing specific chromosomal changes - Your leukemia has high-risk features, including certain gene mutations, complex genetic abnormalities, or detectable residual disease (cancer cells still present after two rounds of chemotherapy) **You may NOT be eligible if...** - Your CBF-AML does not have high-risk features - You have achieved complete molecular remission without detectable residual disease after chemotherapy Talk to your doctor to see if this trial is right for you.